Discounted Cash Flow (DCF) Analysis Unlevered
Regencell Bioscience Holdings Limit... (RGC)
$26.9
-0.64 (-2.32%)
All numbers are in Millions, Currency in USD
Operating Data
Year A/P | 2017 Actual | 2018 Projected | 2019 Projected | 2020 Projected | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | 3,163 | - | - | - | - | - | - | - | - | - | - |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | |||||||||||
| EBITDA | 468.70 | - | - | - | - | - | - | - | - | - | - |
| EBITDA (%) | |||||||||||
| EBIT | 213.90 | - | - | - | - | - | - | - | - | - | - |
| EBIT (%) | |||||||||||
| Depreciation | 254.80 | - | - | - | - | - | - | - | - | - | - |
| Depreciation (%) |
Balance Sheet Data
Year A/P | 2017 Actual | 2018 Projected | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Total Cash | 228.80 | - | - | - | - | - | - | - | - | - | - |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Cash (%) | |||||||||||
| Account Receivables | 184 | - | - | - | - | - | - | - | - | - | - |
| Account Receivables (%) | |||||||||||
| Inventories | 22.90 | - | - | - | - | - | - | - | - | - | - |
| Inventories (%) | |||||||||||
| Accounts Payable | 232.20 | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable (%) | |||||||||||
| Capital Expenditure | -250.40 | - | - | - | - | - | - | - | - | - | - |
| Capital Expenditure (%) |
Weighted Average Cost Of Capital
| Share price | $ 26.9 |
|---|---|
| Beta | 0.000 |
| Diluted Shares Outstanding | 12.64 |
| Cost of Debt | |
| Tax Rate | 1.96 |
| After-tax Cost of Debt | -% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 3.319 |
| Total Debt | 0.77 |
| Total Equity | 340.07 |
| Total Capital | 340.84 |
| Debt Weighting | 0.23 |
| Equity Weighting | 99.77 |
| Wacc |
Build Up Free Cash
Year A/P | 2017 Actual | 2018 Projected | 2019 Projected | 2020 Projected | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | 3,163 | - | - | - | - | - | - | - | - | - | - |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EBITDA | 468.70 | - | - | - | - | - | - | - | - | - | - |
| EBIT | 213.90 | - | - | - | - | - | - | - | - | - | - |
| Tax Rate | 47.50% | 9.89% | 0.00% | 0.00% | 0.00% | 1.96% | 9.89% | 9.89% | 9.89% | 9.89% | 9.89% |
| EBIAT | 112.30 | - | - | - | - | - | - | - | - | - | - |
| Depreciation | 254.80 | - | - | - | - | - | - | - | - | - | - |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - | - |
| Inventories | - | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | - | - | - | - | - | - | - | - | - | - | - |
| Capital Expenditure | -250.40 | - | - | -0.12 | - | -0.78 | - | - | - | - | - |
| UFCF | 116.70 | - | - | - | - | - | - | - | - | - | - |
| WACC | |||||||||||
| PV UFCF | - | - | - | - | - | - | - | - | - | - | |
| SUM PV UFCF | - |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | - |
| Free cash flow (t + 1) | - |
| Terminal Value | - |
| Present Value of Terminal Value | - |
Intrinsic Value
| Enterprise Value | - |
|---|---|
| Net Debt | -5.65 |
| Equity Value | - |
| Shares Outstanding | 12.64 |
| Equity Value Per Share | - |